View Older Stories
-
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
-
MIRA Pharmaceuticals publishes peer-reviewed study on obesity drug candidate
-
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
-
MIRA Pharmaceuticals reports Mira-55 shows no CNS side effects in studies
-
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
-
MIRA Pharmaceuticals completes phase 1 trial for oral pain drug
-
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
-
MIRA Pharmaceuticals starts final cohort of Ketamir-2 phase 1 trial
-
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
-
MIRA Pharmaceuticals begins phase 1 dose study for pain drug
-
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
-
MIRA Pharmaceuticals sells 1.75M shares at 66% premium
-
MIRA Pharmaceuticals reports oral Mira-55 outperformed morphine in pain study
-
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
-
MIRA Pharmaceuticals completes SKNY acquisition, adds $5M in securities
-
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
-
MIRA reports positive Phase 1 trial results for ketamine analog Ketamir-2
-
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
-
Mira Pharma (MIRA) Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
-
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
-
MIRA Pharmaceuticals reports positive preclinical PTSD data for Ketamir-2
-
MIRA Pharmaceuticals shareholders approve SKNY acquisition
-
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
-
MIRA Pharmaceuticals completes Phase 1 trial stage for oral Ketamir-2
-
MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
-
MIRA's Ketamir-2 study accepted for publication in peer-reviewed journal
-
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabal
-
MIRA Pharmaceuticals topical Ketamir-2 matches morphine in preclinical study
-
MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
-
MIRA Pharmaceuticals receives FDA clearance for Ketamir-2 neuropathic pain trial
-
MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
-
MIRA reports anxiety reversal in animal study of obesity drug
-
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
-
Mira Pharma (MIRA) Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
-
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
-
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisitio
-
MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
-
Mira Pharma's (MIRA) Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
-
MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
-
Mira Pharma (MIRA) says Ketamir-2 has been accepted for publication in Frontiers in Pharmacology
-
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
-
Mira Pharma (MIRA) Announces Board Approval of SKNY Acquisition
-
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
-
Mira Pharma (MIRA) Reports No Brain Toxicity in FDA-Required Study of Ketamir-2
-
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
-
Mira Pharma (MIRA) Reports Positive In Vitro Drug Release Data for Topical Ketamir-2
-
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
-
Mira Pharma (MIRA) Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
-
MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
-
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
